RHYTHM PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
RHYTHM PHARMACEUTICALS, INC. (RYTM) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value of $510.14 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue · last filed 2026-02-26
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $510.14M.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $216.41M.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $175.42M.
- 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $73.99M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value |
|---|---|
| 2025-12-31 | $510.14M 10-K · filed 2026-02-26 |
| 2024-12-31 | $216.41M 10-K · filed 2026-02-26 |
| 2023-12-31 | $175.42M 10-K · filed 2024-02-29 |
| 2022-12-31 | $73.99M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |